Oncology Learning Network

Oncology Learning Network
Ixazomib and Daratumumab Demonstrate Tolerable Safety for Elderly Patients with Relapsed/Refractory MM

According to new data, combination ixazomib and daratumumab, without dexamethasone, was tolerable in elderly and frail patients with R/R MM.

Oncology Learning Network
Safety and Tolerability Analysis of Melflufen plus Dexamethasone in Patients with Relapsed/Refractory MM

Safety and tolerability data from the OP-103 study found that melflufen plus dexamethasone remained consistent with prior reports; these data were presented at the 63rd ASH Annual Meeting.

Oncology Learning Network
Ixazomib plus Pomalidomide and Dexamethasone Shows Promise in R/R MM

Results of a phase 1/2 multicenter trial showed that twice-weekly ixazomib added to pomalidomide and dexamethasone treatment was a well-tolerated and promising treatment option...

Oncology Learning Network
Adding Venetoclax to Bortezomib and Dexamethasone Improves PFS in Patients with Relapsed/Refractory MM

The phase 3 BELLINI trial found that adding venetoclax to bortezomib and dexamethasone significantly improved response rates and PFS in patients with R/R MM but also led to increased mortality. 

Oncology Learning Network
Venetoclax plus Daratumumab and Dexamethasone Yields Tolerable Safety in Patients with Relapsed/Refractory MM

According to the preliminary results from the expansion cohort of a phase 1/2 trial presented at the ASH Annual Meeting, VenDd demonstrates a tolerable safety profile in patients with R/R MM. 

Oncology Learning Network
Ruxolitinib with Steroids Shows Promise in Patients with Relapsed/Refractory MM

According to an ongoing phase 1 trial, ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with R/R MM. 

Oncology Learning Network
Novel IMGN632-Based Triplet Yields Anti-Leukemia Activity for R/R AML

Data from a phase 1b/2 study on IMGN632 in combination with azacitidine and venetoclax for patients with R/R AML were presented at the 2021 ASH Annual Meeting.

Oncology Learning Network
John Leonard, MD, Discusses the Lymphoma Treatment Landscape

Dr John P. Leonard discusses the complex landscape and management of patients with lymphoma, as well as hot topics in hematologic malignancies, including the use of monsunetuzumab therapy.

Oncology Learning Network
RNA-Sequencing Consistent With DNA-Sequencing in Detecting RET Fusions

RNA-sequencing showed consistency with DNA-sequencing in detecting RET fusions amongst lung adenocarcinoma through DNA and RNA sequencing, according to a new study. 

Oncology Learning Network
Copanlisib Plus Rituximab Shows Superior Efficacy Over Monotherapy in FL, MZL

Copanlisib when given in combination with rituximab demonstrated superior efficacy when compared to rituximab monotherapy in patients with relapsed FL/MZL, per findings presented at ASH 2021.

Oncology Learning Network
Subscribe to Oncology Learning Network

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb (214, 104, 96)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)